Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Lymphoma

Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial

Abstract

PTCL patients exhibit poor survival with existing treatments. We investigated the efficacy of CHOP combined with alemtuzumab in 116 PTCL patients age 61–80 in an open-label, randomized phase 3 trial. Alemtuzumab was given on day 1, to a total of 360 mg in 21 patients, or 120 mg in 37. Hematotoxicity was increased with A-CHOP resulting in more grade ≥3 infections (40% versus 21%) and 4 versus 1 death due to infections, respectively. CR/CRu rate was 60% for A-CHOP and 43% for CHOP, and OR rate was 72% and 66%, respectively. Three-year-EFS, PFS and OS were 27% [15%–39%], 28% [15%–40%], and 37% ([23%–50%] for A-CHOP, and 24% [12%–35%], 29% [17%–41%], and 56% [44%–69%] for CHOP, respectively, showing no significant differences. Multivariate analyses, adjusted for strata and sex confirmed these results (hazard ratio HREFS: 0.7 ([95% CI: 0.5–1.1]; p = 0.094), HRPFS: 0.8 ([95% CI: 0.5–1.2]; p = 0.271), HROS: 1.4 ([95% CI: 0.9–2.4]; p = 0.154). The IPI score was validated, and male sex (HREFS 2.5) and bulky disease (HREFS 2.2) were significant risk factors for EFS, PFS, and OS. Alemtuzumab added to CHOP increased response rates, but did not improve survival due to treatment-related toxicity.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: CONSORT diagram of the DSHNHL2006-1B/ACT-2 trial.
Fig. 2: Protocol adherence.
Fig. 3: Survival according to treatment arms.
Fig. 4: Survival according to IPI.

References

  1. 1.

    Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.

    CAS  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Wang SS, Vose J. Epidemiology and prognosis of T-Cell lymphoma. In: Foss F editor. T-Cell lymphomas. Springer; New York 2013.

  3. 3.

    Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116:3418–25.

    CAS  PubMed  Google Scholar 

  4. 4.

    Petrich AM, Helenowski IB, Bryan LJ, Rozell SA, Galamaga R, Nabhan C. Factors predicting survival in peripheral T-cell lymphoma in the USA: a population-based analysis of 8802 patients in the modern era. Br J Haematol. 2015;168:708–18.

    PubMed  Google Scholar 

  5. 5.

    Sibon D, Fournier M, Briere J, Lamant L, Haioun C, Coiffier B, et al. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte trials. J Clin Oncol: Off J Am Soc Clin Oncol. 2012;30:3939–46.

    Google Scholar 

  6. 6.

    Sieniawski M, Angamuthu N, Boyd K, Chasty R, Davies J, Forsyth P, et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood. 2010;115:3664–70.

    CAS  PubMed  Google Scholar 

  7. 7.

    Simon A, Peoch M, Casassus P, Deconinck E, Colombat P, Desablens B, et al. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol. 2010;151:159–66.

    PubMed  Google Scholar 

  8. 8.

    Nickelsen M, Ziepert M, Zeynalova S, Glass B, Metzner B, Leithaeuser M, et al. High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Ann Oncol. 2009;20:1977–84.

    CAS  PubMed  Google Scholar 

  9. 9.

    Reimer P, Rudiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009;27:106–13.

    CAS  PubMed  Google Scholar 

  10. 10.

    d’Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093–99.

    PubMed  Google Scholar 

  11. 11.

    Voss MH, Lunning MA, Maragulia JC, Papadopoulos EB, Goldberg J, Zelenetz AD, et al. Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience. Clin Lymphoma, Myeloma Leuk. 2013;13:8–14.

    Google Scholar 

  12. 12.

    Advani RH, Ansell SM, Lechowicz MJ, Beaven AW, Loberiza F, Carson KR, et al. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial. Br J Haematol. 2016;172:535–44.

    CAS  PubMed  Google Scholar 

  13. 13.

    Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30:631–36.

    CAS  PubMed  Google Scholar 

  14. 14.

    Amengual JE, Lichtenstein R, Lue J, Sawas A, Deng C, Lichtenstein E, et al. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood. 2018;131:397–407.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene. 2007;26:3603–13.

    CAS  Google Scholar 

  16. 16.

    Jiang L, Yuan CM, Hubacheck J, Janik JE, Wilson W, Morris JC, et al. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy. Br J Haematol. 2009;145:173–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Karube K, Aoki R, Nomura Y, Yamamoto K, Shimizu K, Yoshida S, et al. Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: analysis of 490 cases. Pathol Int. 2008;58:89–97.

    PubMed  Google Scholar 

  18. 18.

    Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111:5496–504.

    CAS  PubMed  Google Scholar 

  19. 19.

    Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006;24:2472–9.

    CAS  PubMed  Google Scholar 

  20. 20.

    Riechmann L, Foote J, Winter G. Expression of an antibody Fv fragment in myeloma cells. J Mol Biol. 1988;203:825–8.

    CAS  PubMed  Google Scholar 

  21. 21.

    Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature. 1988;332:323–7.

    CAS  PubMed  Google Scholar 

  22. 22.

    Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Dyer MJ, et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res. 1998;22:185–91.

    CAS  PubMed  Google Scholar 

  23. 23.

    Green K, Pearce K, Sellar RS, Jardine L, Nicolson PLR, Nagra S, et al. Impact of Alemtuzumab Scheduling on Graft-versus-Host disease after unrelated donor fludarabine and melphalan allografts. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant. 2017;23:805–12.

    CAS  Google Scholar 

  24. 24.

    Boyd K, Dearden CE. Alemtuzumab in the treatment of chronic lymphocytic lymphoma. Expert Rev anticancer Ther. 2008;8:525–33.

    CAS  PubMed  Google Scholar 

  25. 25.

    Pettitt AR, Jackson R, Carruthers S, Dodd J, Dodd S, Oates M, et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. J Clin Oncol. 2012;30:1647–55.

    CAS  PubMed  Google Scholar 

  26. 26.

    Enblad G, Hagberg H, Erlanson M, Lundin J, MacDonald AP, Repp R, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood. 2004;103:2920–4.

    CAS  PubMed  Google Scholar 

  27. 27.

    Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood. 2007;110:2316–23.

    CAS  PubMed  Google Scholar 

  28. 28.

    Kluin-Nelemans HC, van Marwijk Kooy M, Lugtenburg PJ, van Putten WL, Luten M, Oudejans J, et al. Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Ann Oncol. 2011;22:1595–1600.

    CAS  PubMed  Google Scholar 

  29. 29.

    Binder C, Ziepert M, Pfreundschuh M, Duhrsen U, Eimermacher H, Aldaoud A, et al. CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial. Ann Hematol. 2013;92:1521–1528.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. 30.

    d’Amore F, Leppä S, Silva MGd, Relander T, Lauritzsen GF, Brown PDN, et al. Final analysis of the front-line phase III randomized ACT-1 trial in younger patients with systemic peripheral T-cell lymphoma treated with CHOP chemotherapy with or without Alemtuzumab and consolidated by autologous hematopoietic stem cell transplant. Blood. 2018;132 Suppl 1: 998.

  31. 31.

    Schmitz N, Nickelsen M, Altmann B, Ziepert M, Bouabdallah K, Gisselbrecht C, et al. Allogeneic or autologous transplantation as first-line therapy for younger patients with peripheral T-cell lymphoma: results of the interim analysis of the AATT trial. J Clin Oncol. 2015;33(Suppl 15):8507.

    Google Scholar 

  32. 32.

    Altmann B, Wulf G, Truemper L, d’Amore F, Relander T, Toldbod H, et al. Alemtuzumab added to CHOP for treatment of peripheral T-Cell lymphoma (PTCL) in previously untreated young and elderly patients: pooled analysis of the international ACT-1/2 phase III trials. Blood. 2018;132(Suppl 1):1622.

    Google Scholar 

  33. 33.

    Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–68.

    PubMed  PubMed Central  Google Scholar 

  34. 34.

    Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.

    CAS  PubMed  Google Scholar 

  35. 35.

    Ellin F, Landstrom J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014;124:1570–7.

    CAS  PubMed  Google Scholar 

  36. 36.

    Rodig SJ, Abramson JS, Pinkus GS, Treon SP, Dorfman DM, Dong HY, et al. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res: Off J Am Assoc Cancer Res. 2006;12:7174–9.

    CAS  Google Scholar 

  37. 37.

    Thursky KA, Worth LJ, Seymour JF, Miles Prince H, Slavin MA. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. Br J Haematol. 2006;132:3–12.

    PubMed  Google Scholar 

  38. 38.

    O’Brien S, Ravandi F, Riehl T, Wierda W, Huang X, Tarrand J, et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood. 2008;111:1816–9.

    PubMed  Google Scholar 

  39. 39.

    Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377:2433–44.

    CAS  PubMed  Google Scholar 

  40. 40.

    Clark NM, Grim SA, Lynch JP 3rd. Posaconazole: use in the prophylaxis and treatment of fungal infections. Semin Respiratory Crit Care Med. 2015;36:767–85.

    Google Scholar 

  41. 41.

    Dupuis J, Emile JF, Mounier N, Gisselbrecht C, Martin-Garcia N, Petrella T, et al. Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: A Groupe d’Etude des Lymphomes de l’Adulte (GELA) study. Blood. 2006;108:4163–9.

    CAS  PubMed  Google Scholar 

  42. 42.

    Haverkos BM, Huang Y, Gru A, Pancholi P, Freud AG, Mishra A, et al. Frequency and clinical correlates of elevated plasma Epstein-Barr virus DNA at diagnosis in peripheral T-cell lymphomas. Int J Cancer. 2017;140:1899–906.

    CAS  PubMed  PubMed Central  Google Scholar 

  43. 43.

    Zettl A, Lee SS, Rudiger T, Starostik P, Marino M, Kirchner T, et al. Epstein-Barr virus-associated B-cell lymphoproliferative disorders in angloimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified. Am J Clin Pathol. 2002;117:368–79.

    PubMed  Google Scholar 

  44. 44.

    Abou-Elella AA, Nifong TP. Composite EBV negative peripheral T-cell lymphoma and diffuse large B-cell lymphoma involving the ileum: a case report and a systematic review of the literature. Leuk Lymphoma. 2006;47:2208–17.

    PubMed  Google Scholar 

  45. 45.

    Willenbrock K, Brauninger A, Hansmann ML. Frequent occurrence of B-cell lymphomas in angioimmunoblastic T-cell lymphoma and proliferation of Epstein-Barr virus-infected cells in early cases. Br J Haematol. 2007;138:733–9.

    PubMed  Google Scholar 

  46. 46.

    Hoffmann JC, Chisholm KM, Cherry A, Chen J, Arber DA, Natkunam Y, et al. An analysis of MYC and EBV in diffuse large B-cell lymphomas associated with angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma not otherwise specified. Hum Pathol. 2016;48:9–17.

    CAS  PubMed  Google Scholar 

  47. 47.

    Smuk G, Illes A, Keresztes K, Kereskai L, Marton B, Nagy Z, et al. Pheno- and genotypic features of Epstein-Barr virus associated B-cell lymphoproliferations in peripheral T-cell lymphomas. Pathol Oncol Res. 2010;16:377–83.

    CAS  PubMed  Google Scholar 

  48. 48.

    Gill H, Hwang YY, Chan TS, Pang AW, Leung AY, Tse E, et al. Valganciclovir suppressed Epstein Barr virus reactivation during immunosuppression with alemtuzumab. J Clin Virol. 2014;59:255–8.

    CAS  PubMed  Google Scholar 

  49. 49.

    Gutierrez-Garcia G, Garcia-Herrera A, Cardesa T, Martinez A, Villamor N, Ghita G, et al. Comparison of four prognostic scores in peripheral T-cell lymphoma. Ann Oncol. 2011;22:397–404.

    CAS  PubMed  Google Scholar 

  50. 50.

    Federico M, Rudiger T, Bellei M, Nathwani BN, Luminari S, Coiffier B, et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J Clin Oncol. 2013;31:240–6.

    CAS  PubMed  Google Scholar 

  51. 51.

    Lopez-Guillermo A, Cid J, Salar A, Lopez A, Montalban C, Castrillo JM, et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol. 1998;9:849–55.

    CAS  PubMed  Google Scholar 

  52. 52.

    Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103:2474–9.

    CAS  PubMed  Google Scholar 

  53. 53.

    Kim SJ, Kim K, Kim BS, Kim CY, Suh C, Huh J, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: consortium for improving survival of lymphoma study. J Clin Oncol. 2009;27:6027–32.

    CAS  PubMed  Google Scholar 

  54. 54.

    Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2011;117:3402–8.

    CAS  PubMed  Google Scholar 

  55. 55.

    Torimoto Y, Sato K, Ikuta K, Hayashi T, Hirayama Y, Inamura J, et al. A retrospective clinical analysis of Japanese patients with peripheral T-cell lymphoma not otherwise specified: Hokkaido Hematology Study Group. Int J Hematol. 2013;98:171–8.

    CAS  PubMed  Google Scholar 

  56. 56.

    Abouyabis AN, Shenoy PJ, Lechowicz MJ, Flowers CR. Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States. Leuk Lymphoma. 2008;49:2099–107.

    PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank the patients who participated in this study and their families, as well as the staff at all clinical sites. We gratefully appreciate the commitment of data management staff (Beate Mann, Katja Rillich, Martina Kunert, Barbara Wicklein) at the IMISE, University of Leipzig. We are particularly grateful for the dedicated work of Elke Stitz at the T-NHL office at the UMG.

Funding

Bundesministerium für Bildung und Forschung (BMBF, FKZ 01KG0705); Genzyme-Sanofi (unrestricted grant).

Author information

Affiliations

Authors

Consortia

Contributions

Study conception and design: LT, GGW, NS, MZ, ML. Collection and assembly of data: All authors. Data analysis and interpretation: BA, MZ, ML, GGW, NS, LT. Provision of study materials or patients: All authors. Drafting or revising the manuscript: GGW, BA, MZ, NS, LT. Review and approval of the final version of the manuscript: All authors.

Corresponding author

Correspondence to Gerald G. Wulf.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Members of the ACT-2 study investigators are listed in Supplementary information.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wulf, G.G., Altmann, B., Ziepert, M. et al. Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial. Leukemia 35, 143–155 (2021). https://doi.org/10.1038/s41375-020-0838-5

Download citation

Further reading

Search

Quick links